The advent of Next-Generation Sequencing (NGS) platforms has heightened the demand for advanced statistical methods and bioinformatics tools, essential for the analysis and management of vast datasets. NGS technologies offer progressive advantages in terms of cost-effectiveness, unparalleled sequencing speed, and high resolution, making them indispensable in the fields of oncology and immunology. The synergy between NGS and bioinformatics analysis plays a pivotal role in diagnostics and medical treatment.
With extensive research and development experience in NGS, we introduce the state-of-the-art bioinformatic platform for cancer, providing high-throughput sequencing services and top-tier bioinformatics analysis services.
Whole Genome Sequencing (WGS) Bioinformatics Analysis
Creative Biolabs scientists have crafted a robust pipeline for cancer WGS bioinformatic analysis, emphasizing precision and accuracy. The pipeline encompasses key steps such as quality control of raw data, generation of clean data, unspliced mapping onto a reference genome, post-alignment processing, quality control of mapped reads, and variant calling, annotation, and prioritization.
Whole Exome Sequencing (WES) Bioinformatic Analysis
WES optimizes sequencing and analysis resources by focusing on the most relevant portion of the genome. Particularly beneficial for patients seeking a unified diagnosis for multiple medical problems, WES bioinformatic analysis at Creative Biolabs is conducted with a powerful in-house toolkit. The process ensures highly accurate interpretation, sensitive detection of copy number variations (CNVs), and comprehensive coverage of challenging genes.
Targeted Sequencing Bioinformatics Analysis
Creative Biolabs introduces an efficient tool for targeted sequencing bioinformatics analysis, utilizing mapped reads and targeted region coordinates as input files to generate comprehensive reports. Researchers can provide raw data from NGS runs, and our bioinformatics solutions aid in deciphering base calls. The information provided includes the discovery of germline or somatic mutations, detection and quantification of rare variants, identification of low-frequency alleles, and the recognition of disease-state-associated biomarkers.
In conclusion, the collaboration between NGS and bioinformatics analysis is imperative in the genomic era, and Creative Biolabs stands at the forefront, offering cutting-edge bioinformatics analysis services to unravel the complexities of genomic data in fields such as oncology and immunology.